Skip to content

Study · Animal study (in vivo) · mouse · 2025

5 results

Comparative analysis of short-term and long-term LL-37-induced rosacea-like mouse models: Histopathological features and inflammatory immune responses.

Wu Y, Zhang C, Jin H, Zheng R, Li T, Jin F, Li Y, Gao X, Xu H, Wei Z, Yang J

Animal models and experimental medicine28 Apr 2025Cited by 1 (Europe PMC)

PMID40296272 (opens in a new tab)PMCIDPMC12531105 (opens in a new tab)DOI10.1002/ame2.70020 (opens in a new tab)PepBankPUB-40296272
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In mice, long-term LL‑37 induction produced angiogenesis as part of rosacea-like pathology.

    In plain wordsIn mice, long-term LL‑37 treatment caused new blood vessel growth in the skin, like rosacea.

    Peptide
    LL-37
    Outcome
    IncreaseAngiogenesis with long-term LL-37
    Study

    mousen: not reported in source

    LL-37-induced rosacea-like mouse model
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mice subjected to long-term LL-37 induction developed rosacea-like pathological features, including angiogenesis, thickened skin tissue, and sebaceous gland hypertrophy.
    1 context sentence
    Summary · context
    Accordingly, we aimed to characterize the pathological features of a long-term LL-37-induced mouse model of rosacea and to compare the disease manifestations and pathophysiological characteristics between short-term and long-term LL-37-induced models.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, long-term LL‑37 induction produced thickened skin tissue as part of rosacea-like pathology.

    In plain wordsIn mice, long-term LL‑37 treatment caused thicker skin, like rosacea.

    Peptide
    LL-37
    Outcome
    IncreaseSkin thickening with long-term LL-37
    Study

    mousen: not reported in source

    LL-37-induced rosacea-like mouse model
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mice subjected to long-term LL-37 induction developed rosacea-like pathological features, including angiogenesis, thickened skin tissue, and sebaceous gland hypertrophy.
    1 context sentence
    Summary · context
    Accordingly, we aimed to characterize the pathological features of a long-term LL-37-induced mouse model of rosacea and to compare the disease manifestations and pathophysiological characteristics between short-term and long-term LL-37-induced models.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice, long-term LL‑37 induction produced sebaceous gland hypertrophy as part of rosacea-like pathology.

    In plain wordsIn mice, long-term LL‑37 treatment enlarged the skin oil glands, like rosacea.

    Peptide
    LL-37
    Outcome
    IncreaseSebaceous gland hypertrophy with long-term LL-37
    Study

    mousen: not reported in source

    LL-37-induced rosacea-like mouse model
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mice subjected to long-term LL-37 induction developed rosacea-like pathological features, including angiogenesis, thickened skin tissue, and sebaceous gland hypertrophy.
    1 context sentence
    Summary · context
    Accordingly, we aimed to characterize the pathological features of a long-term LL-37-induced mouse model of rosacea and to compare the disease manifestations and pathophysiological characteristics between short-term and long-term LL-37-induced models.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In the short-term LL‑37 mouse model, immune dysregulation primarily involved the innate immune response.

    In plain wordsIn mice, short-term LL‑37 treatment mainly disturbed the innate immune response.

    Peptide
    LL-37
    Outcome
    IncreaseImmune dysregulation with short-term LL-37
    Study

    mousen: not reported in source

    LL-37-induced rosacea-like mouse model
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the short-term LL-37-induced model, immune dysregulation primarily involved the innate immune response.
    1 context sentence
    Summary · context
    Accordingly, we aimed to characterize the pathological features of a long-term LL-37-induced mouse model of rosacea and to compare the disease manifestations and pathophysiological characteristics between short-term and long-term LL-37-induced models.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice, long-term LL‑37 induction significantly activated both innate and adaptive immune responses.

    In plain wordsIn mice, long-term LL‑37 treatment switched on both innate and adaptive immune responses.

    Peptide
    LL-37
    Outcome
    IncreaseImmune activation with long-term LL-37
    Study

    mousen: not reported in source

    LL-37-induced rosacea-like mouse model
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, long-term LL-37 induction resulted in significant activation of both innate and adaptive immune responses.
    1 context sentence
    Summary · context
    Accordingly, we aimed to characterize the pathological features of a long-term LL-37-induced mouse model of rosacea and to compare the disease manifestations and pathophysiological characteristics between short-term and long-term LL-37-induced models.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.